Memphis Pharmaceuticals and Chemical Industries achieved a notable growth of 9% in its net profits during the first quarter of the fiscal year 2025/2026, with post-tax profits reaching 152.97 million EGP, compared to 140.86 million EGP during the same period of the previous fiscal year.
Read MoreThe Minister of Public Business Sector reviews the executive status of development projects in the 'Pharmaceutical Holding' companies and the introduction of new medicines.
Read MoreMemphis Pharmaceuticals and Chemical Industries achieved a net profit after tax of 375.756 million EGP during the nine months ending last March, compared to 166.368 million EGP in the same period, marking an increase of 125.9%. Gross profit rose, according to the income statement submitted to the Egyptian Stock Exchange today, by 120.7% to 507.305 million EGP during the period from July 2024 to March 2025, compared to 229.864 million EGP in the corresponding period. Memphis Pharmaceuticals' revenues increased by 65.1% to 1.097 billion EGP during the same period, compared to 665.577 million EGP in the equivalent period of the previous year. The gross profit to revenue ratio was 46.2% during the nine months ending last March, compared to 34.6% in the corresponding period.
Read MoreMemphis Pharmaceuticals – a subsidiary of the Holding Company for Pharmaceuticals – is one of the oldest companies operating in the pharmaceutical industry in Egypt and the Middle East, as it was established in 1940. In recent times, the company has been developing its production areas according to Good Manufacturing Practice (GMP) standards and rehabilitating production lines and machinery, as part of the Ministry of Public Business Sector's strategy to revive and develop assets and enhance the production capacity and competitiveness of its affiliated companies.
Read MoreTwo industry giants combine forces in multi-billion dollar deal that will reshape the business landscape and create thousands of new job opportunities.
Read More